View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 29, 2020

BioNTech raises $250m in private funding from Temasek

By Allie Nawrat

BioNTech, the German biotech that is developing a Covid-19 vaccine with Pfizer, has raised $250m in private financing from Temasek and other accredited, unnamed investors.

This private placement includes an investment of $139m in ordinary shares and $112m in four-year mandatory convertible notes.

BioNTech co-founder and CEO Ugur Sahin noted:We are pleased to welcome Temasek onboard as a new shareholder.

“We believe their long-term investment approach, global presence, and deep experience in the biotechnology field are a good fit with our vision to build a leading global biopharmaceutical company.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology